Literature DB >> 28890756

Single-Arm Phase II Group Sequential Trial Design with Survival Endpoint at a Fixed Time Point.

Jianrong Wu1, Xiaoping Xiong1.   

Abstract

In this paper, three non-parametric test statistics are proposed to design single-arm phase II group sequential trials for monitoring survival probability. The small-sample properties of these test statistics are studied through simulations. Sample size formulas are derived for the fixed sample test. The Brownian motion property of the test statistics allowed us to develop a flexible group sequential design using a sequential conditional probability ratio test procedure (Xiong, 1995). An example is given to illustrate the trial design by using the proposed method.

Entities:  

Keywords:  Brownian motion; Interim analysis; Nelson-Aalen estimate; Sample size; Single-arm phase II trial; Survival probability

Year:  2014        PMID: 28890756      PMCID: PMC5589207          DOI: 10.1080/19466315.2014.923325

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  5 in total

1.  Sequential conditional probability ratio tests for normalized test statistic on information time.

Authors:  Xiaoping Xiong; Ming Tan; James Boyett
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  A flexible multi-stage design for phase II oncology trials.

Authors:  Ming T Tan; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2010-12-08       Impact factor: 1.894

3.  Analyzing survival curves at a fixed point in time.

Authors:  John P Klein; Brent Logan; Mette Harhoff; Per Kragh Andersen
Journal:  Stat Med       Date:  2007-10-30       Impact factor: 2.373

4.  Group sequential designs for monitoring survival probabilities.

Authors:  D Y Lin; L Shen; Z Ying; N E Breslow
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

5.  Design of Phase II cancer trials evaluating survival probabilities.

Authors:  L Douglas Case; Timothy M Morgan
Journal:  BMC Med Res Methodol       Date:  2003-04-03       Impact factor: 4.615

  5 in total
  1 in total

1.  Two-stage phase II survival trial design.

Authors:  Jianrong Wu; Li Chen; Jing Wei; Heidi Weiss; Aman Chauhan
Journal:  Pharm Stat       Date:  2019-11-21       Impact factor: 1.234

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.